SBI Holdings, Inc.
SBI Pharmaceuticals Co., Ltd.

SBI Holdings, Inc. (“SBIH”) conducts research and development on cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (5-ALA) at its subsidiary SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative: Yoshitaka Kitao; “SBI Pharmaceuticals”). In relation to this, The University of Hawaii at Manoa Group has recently published the results of clinical studies on the relationship between 5-ALA and glucose levels in the electronic edition of the U.S. science journal Clinical and Translational Science, as described below.

*SBI Pharmaceuticals provided 5-ALA for the above clinical studies, and they were planned, implemented and summarized in a paper under the management of The University of Hawaii.

Journal: Clinical and Translational Science Vol. 5, Issue 4 pages 314 320(2012)

Title: Use of Dietary Supplement 5
Aminolevulinic Acid (5 ALA) and Its Relationship with Glucose Levels and Hemoglobin A1c among Individuals with Predia betes

Summary:
In the studies, examinees with prediabetes (people who are not diabetic now but are at risk of developing diabetes in the future) were divided randomly into two groups. One group took low or high dose s of 5 ALA, and the other took placebos that do not contain 5 ALA. Then, the relationship between the intake of 5 ALA and the ability of cells to absorb sugar (glucose tolerance) was examined. The result s showed that no harmful symptom s caused by 5 ALA w ere found during the three month examination period . In addition, a clear decrease in glucose levels was observed among those who took 5 ALA
two hours after they underwent the oral glucose tolerance test (OGTT).

Reference: Wiley Online Library
(http://onlinelibrary.wiley.com)
The copyright of this lucubration belongs to Wiley Periodicals
Inc

Based on the above results, researchers of The University of Hawaii pointed out that taking 5-ALA could be useful for those with prediabetes, and concluded their paper with the words, “Further investigation of 5-ALA as a dietary supplement in relation to wellness, diabetes and its complications is heartily encouraged.”

SBI Pharmaceuticals will continue to explore various possibilities of utilizing 5-ALA and conduct R&D on it, hoping to contribute to the health of as many people as possible in the world.

＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊
For further information, please contact:
SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126
SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095

Please download PDF File